What is Labviva?
Founded in 2017 and headquartered in Boston, Massachusetts, Labviva operates a sophisticated digital marketplace that connects researchers with a vast network of suppliers for reagents, chemicals, and instrumentation. The platform distinguishes itself by integrating scientific data directly into the purchasing workflow, allowing for a seamless procurement experience across hundreds of global brands.
In an industry traditionally hampered by fragmented supply chains and manual ordering processes, Labviva provides a centralized, data-driven solution. By aligning product discovery with scientific requirements, the company enhances operational efficiency for academic and commercial laboratories, positioning itself as an essential partner in the global life science research and development landscape.
How much funding has Labviva raised?
Labviva has raised a total of $28M across 2 funding rounds:
Angel/Seed
$8M
Series A
$20M
Angel/Seed (2021): $8M with participation from Glasswing Ventures, Senator Investment Group, and B Capital Group
Series A (2023): $20M led by Senator Investment Group, Biospring Partners, Glasswing Ventures, and B Capital Group
Key Investors in Labviva
Glasswing Ventures
Glasswing Ventures invests in visionary, early-stage founders who are leveraging AI and frontier technology to transform enterprise and security markets.
B Capital Group
B Capital is a global venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
Senator Investment Group
Senator Investment Group is a firm that focuses on asset allocation for a variety of public equity and fixed income markets globally.
What's next for Labviva?
With the recent influx of capital, Labviva is well-positioned to scale its enterprise-level operations and deepen its market penetration. The strategic focus will likely center on expanding its supplier network and enhancing the platform's AI-driven procurement capabilities to further streamline the research-to-procurement lifecycle.
As the company transitions into its next phase of growth, the emphasis will remain on maintaining its competitive edge in the life sciences sector. By leveraging the expertise of its high-profile backers, Labviva is poised to redefine how scientific organizations manage their supply chain, ultimately accelerating the pace of innovation in biotechnology and pharmaceutical research.
